BBIO ▼ -2.5% - BridgeBio Pharma, Inc. $BBIO - Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM BridgeBio Pharma's stock declined 2.5% despite positive clinical data showing that acoramidis reversed cardiac structural disease progression and functional decline in ATTR-CM patients while significantly increasing days alive and free from hospitalization. The market reaction suggests investors may have already priced in positive efficacy results, or there are concerns about other factors such as timeline to commercialization, competitive landscape, or regulatory pathway that offset the clinical progress. 30-AUG-2026 10:00 AM ET